New Results
Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
View ORCID ProfileNirmitee Mulgaonkar, View ORCID ProfileHaoqi Wang, View ORCID ProfileSamavath Mallawarachchi, View ORCID ProfileDaniel Ruzek, View ORCID ProfileByron Martina, View ORCID ProfileSandun Fernando
doi: https://doi.org/10.1101/2020.06.18.158196
Nirmitee Mulgaonkar
1Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX 77843, USA
Haoqi Wang
1Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX 77843, USA
Samavath Mallawarachchi
1Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX 77843, USA
Daniel Ruzek
2Veterinary Research Institute, Brno, and Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic
Byron Martina
3Artemis One Health Research Institute, Delft, The Netherlands
Sandun Fernando
1Biological and Agricultural Engineering Department, Texas A&M University, College Station, TX 77843, USA
Article usage
Posted June 18, 2020.
Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
Nirmitee Mulgaonkar, Haoqi Wang, Samavath Mallawarachchi, Daniel Ruzek, Byron Martina, Sandun Fernando
bioRxiv 2020.06.18.158196; doi: https://doi.org/10.1101/2020.06.18.158196
Subject Area
Subject Areas
- Biochemistry (11752)
- Bioengineering (8752)
- Bioinformatics (29200)
- Biophysics (14974)
- Cancer Biology (12096)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14182)
- Epidemiology (2067)
- Evolutionary Biology (18308)
- Genetics (12245)
- Genomics (16803)
- Immunology (11869)
- Microbiology (28097)
- Molecular Biology (11594)
- Neuroscience (60969)
- Paleontology (451)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2886)
- Systems Biology (7340)
- Zoology (1651)